RxDoctor Payments DataLook up a doctor →

Frances Florentino, MD

Dermatology · Evans, GANPI 1255421475

Payments from drug & device makers

$147,908in general payments, 2019–2025

Across 671 payments — averaging $220.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$129K
  • Pfizer$7K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$1K
  • Merz North America, Inc.$1K
  • plus $6K from 29 others

What the payments were for

  • Speaking & faculty fees$5,90030%
  • Food & beverage$12,90466%
  • Education$8114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,908 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$163,141
Medicare patients
747
Services billed
2,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast24$117,805
Cosentyx Unoready PenSecukinumab11$117,028
OpzeluraRuxolitinib Phosphate14$27,722
OraceaDoxycycline Monohydrate12$10,790
Doxycycline Hyclate49$3,935
Clobetasol Propionate120$3,449
Fluorouracil51$3,433
Hydroxychloroquine Sulfate19$780
Ketoconazole40$645
Triamcinolone Acetonide78$608
ValacyclovirValacyclovir Hcl15$420
Fluocinonide14$341
CiclopiroxCiclopirox Olamine14$332
Dutasteride22$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$896$117,80524 claims
Incyte CorporationOpzelura$456$27,72214 claims
Galderma Laboratories, L.p.Oracea$284$10,79012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 345 dermatology providers in Georgia.

Other dermatology in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →